Evan S. Dellon, MD, MPH

University of North Carolina School of Medicine

Poster(s):

• P0390 - Efficacy and Safety of IRL201104, a Novel Peptide Immunomodulator, in a Phase 2a, Double-Blind, Placebo-Controlled Multi-Center Study in Patients With Active Eosinophilic Esophagitis
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0391 - Dupilumab Efficacy in Eosinophilic Esophagitis Persists for Histologic, Symptomatic, and Endoscopic Outcomes Regardless of Concomitant High-Dose Proton Pump Inhibitor Use
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0392 - Dupilumab Improves Dysphagia Symptoms in Adolescent and Adult Patients With Eosinophilic Esophagitis
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0393 - Time on Treatment, Healthcare Resource Utilization, and Costs Associated with Topical Corticosteroids and Proton Pump Inhibitors in Patients with Eosinophilic Esophagitis in the United States
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0394 - Telehealth Is an Acceptable and Feasible Option for Patients with Eosinophilic Gastrointestinal Diseases: Data From the Online EGID Partners Cohort
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P0395 - Retrospective Assessment of the Index of Severity for Eosinophilic Esophagitis Using Baseline Disease Characteristics Data from the LIBERTY EoE TREET Study
  Sunday, October 22, 2023

  3:30 PM – 7:00 PM PT

• P4186A - An Adaptive Phase 2/3 Study Design to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Adults and Adolescents With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT